Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WARD J PAINE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1518918614
CMS profile
23826
Location
MORGANTOWN, WV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,572.57

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,070.22 49
Travel and Lodging $482.13 9
Education $20.22 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WARD J PAINE

NPI 1518918614 · CMS profile ID 23826

Allopathic & Osteopathic Physicians / Internal Medicine

MORGANTOWN, WV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518918614?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WARD J PAINE, NPI 1518918614, CMS profile ID 23826. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518918614?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). WARD J PAINE, NPI 1518918614, CMS profile ID 23826. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518918614?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
WARD J PAINE, NPI 1518918614, CMS profile ID 23826, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1518918614?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $1,572.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $13.1503/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125106900 CMS
Dexcom, Inc. $14.1103/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153343523 CMS
Amgen Inc. $14.5503/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117647725 CMS
ABBVIE INC. $13.3702/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105170396 CMS
ABBVIE INC. $17.8302/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105170394 CMS
AstraZeneca Pharmaceuticals LP $15.6801/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105537555 CMS
Novo Nordisk Inc $18.7601/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097574777 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.9501/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118042484 CMS
Lilly USA, LLC $13.1501/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135477038 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,251.84 90
PY2020 $388.80 26
PY2021 $422.85 26
PY2022 $655.93 33
PY2023 $751.54 33
PY2024 $1,572.57 59
PY2025 $559.93 29

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $772,831.32 51
PY2024 Recipient $28,819.67 5
PY2024 Principal investigator $1,187,439.34 87
PY2023 Recipient $7,075.62 2
PY2023 Principal investigator $1,271,587.07 38
PY2022 Recipient $26,286.00 1
PY2022 Principal investigator $1,547,485.10 9
PY2021 Principal investigator $60,761.58 5
PY2020 Principal investigator $40,257.65 7
PY2019 Principal investigator $202,568.24 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,835.00 11/26/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH, LLC
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185555768
Principal investigator 1 AstraZeneca Pharmaceuticals LP $40,406.38 11/26/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH, LLC
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) No dispute reported 06/30/2026 1185555774
Principal investigator 1 Genentech, Inc. $3,330.00 09/24/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607677
Principal investigator 1 Genentech, Inc. $7,872.00 09/05/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607703
Principal investigator 1 Genentech, Inc. $170.00 09/03/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607680
Principal investigator 1 ModernaTX, Inc. $53.58 08/28/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005845
Principal investigator 1 AstraZeneca Pharmaceuticals LP $63,335.20 08/07/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH, LLC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185555778
Principal investigator 1 Amgen Inc. $20,470.00 08/01/2025 Non-covered Recipient Entity
IM SUPER HOLDINGS LLC DBA IMA CLINICAL RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246642531
Principal investigator 1 Genentech, Inc. $1,298.00 07/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607693
Principal investigator 1 Genentech, Inc. $196.00 07/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607646
Principal investigator 1 Genentech, Inc. $170.00 07/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607701
Principal investigator 1 ModernaTX, Inc. $18,331.33 06/20/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005831
Principal investigator 1 Genentech, Inc. $2,700.00 06/18/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607608
Principal investigator 1 ModernaTX, Inc. $9,590.82 05/28/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005833
Principal investigator 1 ModernaTX, Inc. $1,450.80 05/28/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005835
Principal investigator 1 ModernaTX, Inc. $28,989.08 05/28/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005839
Principal investigator 1 Eli Lilly and Company $829.61 05/27/2025 Non-covered Recipient Entity
MEDEX HEALTHCARE RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187884750
Principal investigator 1 Genentech, Inc. $1,154.00 05/21/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607616
Principal investigator 1 Genentech, Inc. $5,000.00 05/07/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607612
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,867.00 05/02/2025 Non-covered Recipient Entity
IMA EVALUATIONS, INC.
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185555770
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,450.00 04/30/2025 Non-covered Recipient Entity
AGA CLINICAL TRIALS
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185555766
Principal investigator 1 ModernaTX, Inc. $5,803.20 04/28/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005837
Principal investigator 1 ModernaTX, Inc. $28,562.77 04/28/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005849
Principal investigator 1 ModernaTX, Inc. $12,055.50 04/28/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005855
Principal investigator 1 Eli Lilly and Company $2,792.22 03/25/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187883602
Principal investigator 1 ModernaTX, Inc. $8,704.80 03/24/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005851
Principal investigator 1 ModernaTX, Inc. $11,144.64 03/24/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005857
Principal investigator 1 Genentech, Inc. $588.00 03/21/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607432
Principal investigator 1 Genentech, Inc. $935.00 03/19/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607473
Principal investigator 1 Eli Lilly and Company $15,446.00 03/11/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187881912
Principal investigator 1 Eli Lilly and Company $1,202.00 03/10/2025 Non-covered Recipient Entity
M SUPER HOLDINGS LLC IMA EVALUATIONS LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885766
Principal investigator 1 ModernaTX, Inc. $5,427.92 02/27/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005829
Principal investigator 1 ModernaTX, Inc. $27,710.15 02/27/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005847
Principal investigator 1 ModernaTX, Inc. $2,601.40 02/27/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005853
Principal investigator 1 ModernaTX, Inc. $40,131.42 02/27/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005859
Principal investigator 1 ModernaTX, Inc. $7,254.00 02/27/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005861
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,224.73 02/26/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH, LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185555772
Principal investigator 1 Amgen Inc. $8,030.70 02/25/2025 Non-covered Recipient Entity
IMA CLINICAL RESEARCH - WEST VIRGINIA
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246642553
Principal investigator 1 Eli Lilly and Company $18,765.00 02/03/2025 Non-covered Recipient Entity
M SUPER HOLDINGS LLC IMA EVALUATIONS LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885764
Principal investigator 1 Eli Lilly and Company $65.00 01/31/2025 Non-covered Recipient Entity
M SUPER HOLDINGS LLC IMA EVALUATIONS LLC
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187884212
Principal investigator 1 Genentech, Inc. $1,921.00 01/29/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607497
Principal investigator 1 ModernaTX, Inc. $44,645.40 01/29/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005825
Principal investigator 1 ModernaTX, Inc. $8,704.80 01/29/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005827
Principal investigator 1 ModernaTX, Inc. $5,202.80 01/29/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005843
Principal investigator 1 ModernaTX, Inc. $15,773.47 01/29/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005863
Principal investigator 1 AstraZeneca Pharmaceuticals LP $40,367.60 01/17/2025 Non-covered Recipient Entity
IMA EVALUATIONS, INC.
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185555776
Principal investigator 1 Genentech, Inc. $255.00 01/13/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607465
Principal investigator 1 ModernaTX, Inc. $500.00 01/13/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005841
Principal investigator 1 Eli Lilly and Company $63,260.00 01/07/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187882626
Principal investigator 1 Eli Lilly and Company $42,357.00 01/06/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187882676
Principal investigator 1 Eli Lilly and Company $89,901.00 01/06/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC DBA IMA CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187883592